1. 人免疫球蛋白联合 IMP/CS 和 PS/TS 对重症肺部感染患者炎性因子 及 T 细胞亚群的影响.
- Author
-
巫海龙, 冒山林, 李向宇, 顾 莹, and 郁 翰
- Subjects
- *
DRUG side effects , *LUNG infections , *C-reactive protein , *T cells , *PIPERACILLIN - Abstract
Objective : To explore the efficacy of human immunoglobulin (HIG) combined with imipenem-cilastatin sodium (IMP/CS) and piperacillin tazobactam sodium (PS/TS) in the treatment of severe pulmonary infection. Method : 99 cases patients with severe pulmonary infection who were admitted to North Hospital of Huashan Hospital Affiliated to Fudan University from March 2013 to July 2018 were selected as the study subjects. They were randomly divided into group A (33 cases, treated with HIG+IMP/CS+PS/TS), group B (33 cases, treated with IMP/CS+PS/TS) and group C (33 cases, treated with PS/TS). The effectiveness, inflammatory factors, T cell subsets and adverse reactions were observed. Result : The total clinical effective rate of group A was 96.97%, which was higher than 78.79% of group B, and that in group B was higher than 60.61% of group C (P<0.05). 7 days after treatment, the levels of C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-α(TNF-α) and CD8+ in the three groups were lower than those before treatment, the CD4+ and CD4+ /CD8+ were higher than those before treatment the difference were with statistically significance (P<0.05). 7 days after treatment, the levels of CRP, IL-6, TNF-α, CD8+ in group A were lower than those in group B, and those in group B were lower than those in group C (P<0.05). 7 days after treatment, the CD4+ and CD4+ /CD8+ in group A were higher than those in group B, and those in group B were higher than those in group C (P<0.05). No adverse drug reactions occurred in the three groups during the treatment. Conclusion : HIG combined with IMP/CS and PS/TS is safe and effective in the treatment of severe pulmonary infection. It can effectively improve the inflammatory response, regulate immune function and promote the recovery of patients. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF